About NH HEALTH Company

In 2015, Novartis Health was founded in Hangzhou, Zhejiang. It was the first biotech company in China focusing on early screening for high-incidence cancers at home. It was also the first in the industry to successfully list on the Hong Kong Stock Exchange, becoming the “first stock in early cancer screening in China”, stock code 6606.HK. With the mission of “changing the trajectory of life”, Nuohui Health adheres to the product concept that has a scientific basis, clinical verification, user needs, and market prospects, and invests heavily in self-developed multi-omics cancer screening technology innovation and product development. In response to colorectal cancer and stomach cancer, which are currently the most common digestive tract cancers in China, the company has separately listed and commercialized three pioneering star products in the industry: Chang Weiqing, Pu Pu, and Pu Yu. Chang Weiqing is the first cancer screening product approved by China's National Drug Administration. It is suitable for people aged 40 to 74 at high risk of colorectal cancer. Youtube is the first Helicobacter pylori consumer self-test product approved by China's National Drug Administration. The Pooh Tube is the first Fecal Blood (FIT) home self-tester approved in China. In addition, the company has three clinical products under development or about to be registered for screening for liver cancer (), cervical cancer (Gong zhengqing), and nasopharyngeal cancer (), as well as a number of other cancer screening pipeline products. The company holds global intellectual property rights for all of its listed and pipeline products. Based on the clinical market, Novartis Health has pioneered diversified business models in the early cancer screening industry, and has established extensive strategic cooperation with leading cross-border brands such as well-known medical examination chains, insurance companies, pharmacy chains, and various Internet medical platforms. The company's main products have entered nearly 1,000 hospitals across the country, forming a closed-loop early screening, diagnosis and treatment service combining outpatient and in-hospital physical examinations. Based on the domestic market, Novartis Health began overseas market exploration in 2022. In June, Novartis Health joined hands with US NASDAQ listed company Prenetics to launch Chang Weiqing in Hong Kong, China, and plans to gradually cover Macau and Taiwan in the future, thereby entering the Southeast Asian market. The company began construction of its first international R&D center at the Hong Kong Science and Technology Park at the same time, focusing on multi-omics R&D and product development including second-generation sequencing technology (NGS). Novartis Health, a publicly traded company, participated in the establishment of the NHH Venture Fund (NHH Venture Fund) in August 2021 to focus on investing in breakthrough innovative molecular diagnostic technology for major human diseases. Up to now, the company has reached investments or strategic partnerships with five of the world's leading cancer screening or testing biotech companies in the US, Germany, Switzerland and Singapore. Novartis Health has a 100,000 grade clean production workshop in Hangzhou that complies with ISO 13485 and ISO 9001 international certification standards, and has third party medical testing laboratories in Beijing, Hangzhou and Guangzhou. All three laboratories have obtained relevant international standard quality system certification and certification from the local Health and Health Commission and issued a license to practice.